New board appointment for CRT

2013-08-21 00:00:00

Cancer Research Technology has announced the appointment of Ruth McKernan as a non-executive director. Ruth is currently Senior Vice President and Chief Scientific Officer of Pfizer’s Neusentis Research Unit in Cambridge UK.

Prior to leading Neusentis, Ruth started Pfizer’s Regenerative Medicine Unit, was Site Head and Head of Research at the company’s former European R&D site in Sandwich, UK and was Head of Pfizer’s Research Technology Centre in Boston, MA.

Before joining Pfizer, Ruth worked for Merck Research Labs for 17 years and was the Head of Merck’s Neuroscience Centre in Harlow. She is a member of the UK board of Pfizer Ltd., a visiting Professor at Kings College, London as well as a member of Council at the MRC.

Ruth succeeds Barrie Ward (formerly CEO KuDos, chairman of AVANT Immunotherapeutics Inc) who is stepping down after serving for a period of 7 years.

Notes to editors